PMV Pharmaceuticals Inc.
(PMVP)
undefined
undefined%
At close: undefined
1.58
-0.32%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMV Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Dr. David H. Mack Ph.D. |
Contact Details
Address: 8 Clarke Drive Cranbury, New Jersey United States | |
| Website | https://www.pmvpharma.com |
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| Employer ID | 46-3218129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Michael Carulli | Chief Financial Officer |
| Crystal Zuckerman | Vice President of Human Resources |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Director & Member of Scientific Advisory Board |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery & CMC |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Dr. Marc Fellous M.D. | Senior Vice President and Head of Clinical Development & Medical Affairs |
| Laura De Leon | Vice President & Head of Clinical Operations |
| Robert Ticktin J.D. | General Counsel, Head of Operations & Company Secretary |
| Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 27, 2024 | 424B3 | Filing |
| Nov 20, 2024 | S-3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Sep 12, 2024 | 4 | Filing |